MetaCap

Aldeyra Therapeutics Inc. (ALDX)

NASDAQ: ALDXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.84+0.1183 (+16.39%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ALDX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$50.70M
EPS (TTM)
-$0.31
52-week range
0.527 – 5.93
Day range
0.6589 – 0.8849
Volume / Avg
2.47M / 1.16M
Beta
—

52-week range

$0.527$5.93

ALDX stock today

Aldeyra Therapeutics (ALDX) closed at $0.84 on Nov 20, up 16.39% (+$0.1183), versus the S&P 500's 3.70% decline. Volume was 2.1x the average at 2.47M shares, a sign of unusually heavy trading. Shares are 85.8% below their 52-week high of $5.93, set on Jan 30, 2026 and 59.4% above the 52-week low of $0.527, near the bottom of the past year's range.

ALDX is down 83.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 83.1%. Aldeyra Therapeutics has posted a net loss over the last twelve months (EPS of -$0.31), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Aldeyra Therapeutics

Company profile

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Todd C. Brady M.D., Ph.D.
Headquarters
Lexington, MA
Employees
6
IPO year
2014

Financial highlights

Full financials

Aldeyra Therapeutics reported a net loss of $33.8 million, compared with a loss of $55.9 million a year earlier. Diluted earnings per share came in at -$0.56.

Aldeyra Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-33.85M$-55.85M$-37.54M$-62.02M$-57.78M
EPS (diluted)$-0.56$-0.94$-0.64$-1.06$-1.07

Analyst forecast

Forecast

Consensus (6 analysts)

strong_buy

Avg. price target

$6.60+685.71%

  • Strong buy 1
  • Buy 4
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $2.00High $13.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.06 vs $-0.11
Surprise
+45.45%

ALDX news

All ALDX news

Aldeyra Therapeutics peers

Health Care sector
ALDX peer companies
CompanyPrice% ChgMarket capCompare
CLNNClene Inc.3.52+0.57%$50.69Mvs ALDX
ACRVAcrivon Therapeutics Inc.1.15-17.86%$49.35Mvs ALDX
LFVNLifevantage Corporation4.15-15.13%$52.63Mvs ALDX
XBITXBiotech Inc.1.73+2.98%$52.74Mvs ALDX
CTORCitius Oncology Inc.0.5035-10.95%$53.25Mvs ALDX
HRTXHeron Therapeutics Inc.0.2525-4.39%$48.04Mvs ALDX
XLOXilio Therapeutics Inc.7.56-1.11%$53.40Mvs ALDX
RFLRafael Holdings Inc. Class B0.9197+2.19%$47.99Mvs ALDX

Indexes, lists and sector

Aldeyra Therapeutics stock FAQ

What is Aldeyra Therapeutics's stock price today?

ALDX last traded at $0.84 as of Nov 20, 4:00 PM EST, up 16.39% on the day. Prices are delayed at least 15 minutes.

Who is Aldeyra Therapeutics's CEO?

Dr. Todd C. Brady M.D., Ph.D. is the chief executive officer of Aldeyra Therapeutics Inc., which has about 6 employees.

What is the ALDX 52-week high?

The 52-week high for ALDX is $5.93 and the 52-week low is $0.527. The stock is currently 85.8% below its high.

Compare ALDX